Mounjaro®

Company: Eli Lilly and Company

Therapeutic Area: Diabetes, Weight Management

Drug Type: Peptide Therapeutics

Molecule: Tirzepatide

Clinical Phase: Approved

Pipeline Status: Active

Indication: 1. Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 2. FDA-approved for use in children and adolescents aged 10 years and older with type 2 diabetes, indicated as an adjunct to diet and exercise to help lower hemoglobin A1c.

Mechanism of Action: Dual GIP/GLP-1 Receptor Agonist Mounjaro is a single molecule that activates the body's receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which are natural incretin hormones, making it the first and only approved therapy of its class.

Approved Countries

• UNITED STATES
• EUROPEAN UNION
• UNITED KINGDOM
• INDIA
• JAPAN
• CANADA
• AUSTRALIA